Playlist


National Leader of the Turkmen People Congratulates Uzbek Singer Farrukh Zakirov on Jubilee
11 May. 06:12The international equestrian festivals recently held in Uzbekistan featured prominent performances by leading cultural figures and artists from across the region. Among the distinguished participants was the legendary singer and People's Artist of Uzbekistan, Farrukh Zakirov. His presence at the celebrations added a significant cultural dimension to the events, highlighting the shared artistic heritage of the Turkmen and Uzbek peoples.
To mark the singer's recent milestone birthday, the National Leader of the Turkmen People, Chairman of the Halk Maslahat Gurbanguly Berdimuhamedov, sent his warm congratulations and a special commemorative gift. This gesture reflects the high esteem in which the artist is held in Turkmenistan and underscores the importance of cultural diplomacy in strengthening bilateral ties between the two neighboring nations.
Accepting the gift with great appreciation, Farrukh Zakirov expressed his profound gratitude to the National Leader of Turkmenistan. He noted that such personal attention from the Turkmen leadership is a testament to the enduring friendship and mutual respect that exist between the two nations. The artist emphasized his commitment to further promoting cultural exchange and unity through his musical endeavors.
The cultural partnership between Turkmenistan and Uzbekistan continues to flourish, rooted in centuries of shared history and traditions. This high-level recognition of an artist's contributions serves as a powerful symbol of regional solidarity and spiritual proximity. The event was widely reported as a successful example of utilizing the arts to reinforce diplomatic and fraternal bonds.
Also read


Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds
Today in 02:02Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.
Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.